Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients

Journal of Hypertension

Volumn 31, Issue 12, 2013, Pages 2425-2432

  Kwakernaak, Arjan J ^a   Waanders, Femke ^a   Slagman, Maartje C J ^a   Dokter, Martin M ^a   Laverman, Gozewijn D ^a,b   De Boer, Rudolf A ^a   Navis, Gerjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TWENTEBORG HOSPITAL   (Netherlands)

Author keywords

chronic kidney disease; fibrosis; inflammation; N acetyl seryl aspartyl lysyl proline; renoprotection; sodium restriction

Indexed keywords

CALCIUM; CREATININE; LISINOPRIL; N ACETYL SERYL ASPARTYL LYSYL PROLINE; PROTEIN; TETRAPEPTIDE; UNCLASSIFIED DRUG; VALSARTAN;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIET; DISEASE SEVERITY; FEMALE; HUMAN; HYPOTHESIS; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; SODIUM RESTRICTION; TREATMENT OUTCOME;

ACETYLATION; ADULT; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OLIGOPEPTIDES; RENIN-ANGIOTENSIN SYSTEM; SODIUM, DIETARY;

EID: 84888138002     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328364f5de     Document Type: Article

References (54)

1. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
2. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349:1857-1863.
3. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19:999-1007.
4. Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011; 343:d4366.
5. Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012; 23:165-173.
6. Heerspink HJ, Holtkamp FA, Parving HH, Navis GJ, Lewis JB, Ritz E, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012; 82:330-337.
7. Kramer AB, Bos H, van Goor H, Navis GJ. Sodium intake modifies the negative prognostic value of renal damage prior to treatment with ACE inhibitors on proteinuria induced by adriamycin. Nephron Physiol 2006; 103:43-52.
8. Kocks MJ, Lely AT, Boomsma F, de Jong PE, Navis G. Sodium status and angiotensin-converting enzyme inhibition: effects on plasma angiotensin-( 1-7) in healthy man. J Hypertens 2005; 23:597-602.
9. Kocks MJ, Gschwend S, de Zeeuw D, Navis G, Buikema H. Low sodium modifies the vascular effects of angiotensin-converting enzyme inhibitor therapy in healthy rats. J Pharmacol Exp Ther 2004; 310:1183-1189.
10. Vogt L, Kocks MJ, Laverman GD, Navis G. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and nondiabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Minerva Med 2004; 95:395-409.
11. van der Kleij FG, de Jong PE, Henning RH, de Zeeuw D, Navis G. Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. J Am Soc Nephrol 2002; 13:1025-1033.
12. Slagman MC, Nguyen TQ, Waanders F, Vogt L, Hemmelder MH, Laverman GD, et al. Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy. Clin J Am Soc Nephrol 2011; 6:1845-1850.
13. Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, et al. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998; 98:2621-2628.
14. Pradelles P, Frobert Y, Creminon C, Ivonine H, Frindel E. Distribution of a negative regulator of haematopoietic stem cell proliferation (AcSDKP) and thymosin beta 4 in mouse tissues. FEBS Lett 1991; 289:171-175.
15. Pradelles P, Frobert Y, Creminon C, Liozon E, Masse A, Frindel E. Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochem Biophys Res Commun 1990; 170:986-993.
16. Rhaleb NE, Pokharel S, Sharma U, Carretero OA. Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice. J Hypertens 2011; 29:330-338.
17. Wang M, Liu R, Jia X, Mu S, Xie R. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal inflammation and tubulointerstitial fibrosis in rats. Int J Mol Med 2010; 26:795-801.
18. Sharma U, Rhaleb NE, Pokharel S, Harding P, Rasoul S, Peng H, et al. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol 2008; 294:H1226-H1232.
19. Cavasin MA, Liao TD, Yang XP, Yang JJ, Carretero OA. Decreased endogenous levels of Ac-SDKP promote organ fibrosis. Hypertension 2007; 50:130-136.
20. Pokharel S, van Geel PP, Sharma UC, Cleutjens JP, Bohnemeier H, Tian XL, et al. Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation 2004; 110:3129-3135.
21. Peng H, Carretero OA, Liao TD, Peterson EL, Rhaleb NE. Role of Nacetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension. Hypertension 2007; 49:695-703.
22. Kanasaki M, Nagai T, Kitada M, Koya D, Kanasaki K. Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair 2011; 4:1-12.
23. Omata M, Taniguchi H, Koya D, Kanasaki K, Sho R, Kato Y, et al. Nacetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established antiglomerular basement membrane nephritis. J Am Soc Nephrol 2006; 17:674-685.
24. Lin CX, Rhaleb NE, Yang XP, Liao TD, D'Ambrosio MA, Carretero OA. Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 2008; 295:H1253-H1261.
25. Chen YW, Liu BW, Zhang YJ, Chen YW, Dong GF, Ding XD, et al. Preservation of basal AcSDKP attenuates carbon tetrachloride-induced fibrosis in the rat liver. J Hepatol 2010; 53:528-536.
26. Liu YH, D'Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, et al. Nacetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growthregulatory lectin. Am J Physiol Heart Circ Physiol 2009; 296:H404-H412.
27. Yang F, Yang XP, Liu YH, Xu J, Cingolani O, Rhaleb NE, et al. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 2004; 43:229-236.
28. Haznedaroglu IC, Ozturk MA. Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. Int J Biochem Cell Biol 2003; 35:867-880.
29. Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl (119):2010;S22-S26.
30. Rodriguez-Iturbe B, Garcia GG. The role of tubulointerstitial inflammation in the progression of chronic renal failure. Nephron Clin Pract 2010; 116:c81-c88.
31. Shibuya K, Kanasaki K, Isono M, Sato H, Omata M, Sugimoto T, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes 2005; 54:838-845.
32. Liao TD, Yang XP, D'Ambrosio M, Zhang Y, Rhaleb NE, Carretero OA. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: Council for High Blood Pressure Research. Hypertension 2010; 55:459-467.
33. Jablonski KL, Gates PE, Pierce GL, Seals DR. Low dietary sodium intake is associated with enhanced vascular endothelial function in middleaged and older adults with elevated systolic blood pressure. Ther Adv Cardiovasc Dis 2009; 3:347-356.
34. Dickinson KM, Keogh JB, Clifton PM. Effects of a low-salt diet on flow-mediated dilatation in humans. Am J Clin Nutr 2009; 89:485-490.
35. Jablonski KL, Racine ML, Geolfos CJ, Gates PE, Chonchol M, McQueen Scd MB, et al. Dietary sodium restriction reverses vascular endothelial dysfunction in middle-aged/older adults with moderately elevated systolic blood pressure. J Am Coll Cardiol 2013; 61:335-343.
36. Ingert C, Grima M, Coquard C, Barthelmebs M, Imbs JL. Effects of dietary salt changes on renal renin-angiotensin system in rats. Am J Physiol Renal Physiol 2002; 283:F995-F1002.
37. Hamming I, van Goor H, Turner AJ, Rushworth CA, Michaud AA, Corvol P, et al. Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats. Exp Physiol 2008; 93:631-638.
38. Fox J, Guan S, Hymel AA, Navar LG. Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats. Am J Physiol 1992; 262 (5 Pt 2):F902-F909.
39. Kocks MJ, Buikema H, Gschwend S, Boomsma F, de Zeeuw D, Navis G. High dietary sodium blunts affects of angiotensin-converting enzyme inhibition on vascular angiotensin I-to-angiotensin II conversion in rats. J Cardiovasc Pharmacol 2003; 42:601-606.
40. Armbrust T, Batusic D, Ringe B, Ramadori G. Mast cells distribution in human liver disease and experimental rat liver fibrosis. Indications for mast cell participation in development of liver fibrosis. J Hepatol 1997; 26:1042-1054.
41. Terwel D, Bothmer J, Wolf E, Meng F, Jolles J. Affected enzyme activities in Alzheimer's disease are sensitive to antemortem hypoxia. J Neurol Sci 1998; 161:47-56.
42. Oudot C, Lajoix AD, Jover B, Rugale C. Oxydative stress and beneficial effect of sodium restriction on kidney damage associated with insulin resistance in rats. Ann Cardiol Angeiol (Paris) 2012; 61:162-166.
43. Krikken JA, Lely AT, Bakker SJ, Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 2007; 71:260-265.
44. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160:685-693.
45. Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011; 80:282-287.
46. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51:793-797.
47. Beige J, Heipmann K, Stumvoll M, Korner A, Kratzsch J. Paradoxical role for adiponectin in chronic renal diseases? An example of reverse epidemiology. Expert Opin Ther Targets 2009; 13:163-173.
48. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
49. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204-2213.
50. Catapano F, Chiodini P, De NL, Minutolo R, Zamboli P, Gallo C, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52:475-485.
51. Slagman MC, Navis G, Laverman GD. Dual blockade of the reninangiotensin-aldosterone system in cardiac and renal disease. Curr Opin Nephrol Hypertens 2010; 19:140-152.
52. van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, et al. Levels of hematopoiesis inhibitor N-acetyl-serylaspartyl- lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 2005; 112:1743-1747.
53. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysylproline. J Clin Invest 1996; 97:839-844.
54. Azizi M, Ezan E, Nicolet L, Grognet JM, Menard J. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 1997; 30:1015-1019.